| abstract |
The present invention relates to a combination comprising gemigliptin, which is a peptidase IV inhibitor or a pharmaceutically acceptable salt thereof, and rosuvastatin, which is an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof. Furthermore, it may comprise stabilizers, binders, disintegrants, glidants, bulking agents and the like as pharmaceutically acceptable excipients. Said preparation serves to effectively treat type 2 diabetes mellitus and dyslipidemia in diabetic patients. |